Is AFL a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Japan third-sector product refresh, with revenue (ttm) at ~$18.2 billion (FY2025 was ~$17.2 billion, down ~9.3% year over year). The bear case rests on the dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect. Analysts covering it are spread from $98.00 to $137.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $98.00, -21.9% from the $125.56 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Japan third-sector product refresh. Aflac Japan is trying to replace a shrinking in-force block with new sales to younger policyholders, and the Miraito cancer product plus the Tsumitasu medical launch drove a sales increase above 20% in recent quarters. The most optimistic analyst target on AFL is $137.00, +9.1% from the $125.56 price. That figure is only reachable if this thesis works close to its best case.

The dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect. The second is demographic and structural, because Japan's population is aging and shrinking, the existing cancer and medical block keeps rolling into paid-up status, and net earned premiums there have been declining year over year. A third is that the company faces litigation exposure, including class actions stemming from the June 2025 cyberattack on its network that exposed customer data, plus longstanding disputes with sales associates over classification and sales practices. Interest rate volatility affects both investment income and the valuation of a large fixed-income portfolio, and a sharp move in Japanese government bond yields would hit the Japan investment book directly. Finally, the valuation carries little margin for disappointment: at roughly 14 times trailing earnings and about 2.1 times stated book value, with a modest dividend yield near 2%, most of the return has to come from execution on Japan sales and the buyback rather than multiple expansion. The most pessimistic published target is $98.00, -21.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Aflac is the largest US provider of supplemental health insurance sold at the worksite, and the leading writer of cancer and medical policies in Japan, which supplies most of its earnings.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Japan third-sector product refresh) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Supplemental insurance: cash-benefit policies that pay the policyholder directly when a covered event occurs, such as a cancer diagnosis, a hospital admission, an accident or a critical illness. These sit alongside major medical coverage rather than replacing it. In the US the policies are sold mostly at the worksite through payroll deduction, and in Japan cancer and medical insurance are sold through banks, independent agencies and the Japan Post network.

Aflac Japan is the larger of the two segments and typically contributes the majority of pretax adjusted earnings, at ~$759 million in Q1 2026 versus ~$363 million for Aflac US. That means most of the profit is earned in yen and translated into dollars, so currency moves change reported results even when policy sales and claims are unchanged. It also means Japanese demographics and product regulation drive the company's growth outlook more than US conditions do.

It is generally held for that reason. Aflac raised its quarterly dividend 5.2% for 2026, marking 43 consecutive years of increases, and the annualized payout of ~$2.44 per share works out to a yield near ~2.0% at recent prices. The payout ratio is low relative to earnings, and the company has historically directed more cash to buybacks than to dividends, repurchasing ~$1.0 billion of stock in Q1 2026 alone.